Despite Quest Diagnostics' outperformance relative to its industry peers over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Quest Diagnostics (NYSE:DGX) has had a great run on the share market with its stock up by a significant 7.3% over the last month. As most would know, fundamentals are what usually guide market ...

With a market cap of $20 billion, Quest Diagnostics Incorporated (DGX) is a leading provider of diagnostic testing services ...

Quest Diagnostics’ string of acquisitions is also expected to have bolstered its performance in the to-be-reported quarter. ... a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), ...

Quest Diagnostics' (NYSE:DGX) stock up by 2.7% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance.

Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over-year to $2.39 billion. The company raised its fiscal year 2024 ...

This was the stock's second consecutive day of losses.

Morgan Stanley analyst Erin Wright has maintained their bullish stance on DGX stock, giving a Buy rating yesterday. Erin Wright has given his Buy rating due to a combination of factors that ...

Michael Cherny, an analyst from Leerink Partners, maintained the Hold rating on Quest Diagnostics (DGX – Research Report). The associated price target is $169.00. Don't Miss our Black Friday ...

Quest Diagnostics (NYSE:DGX) has had a great run on the share market with its stock up by a significant 13% over the last three months. Given that stock prices are usually aligned with a company's ...